Suchergebnisse - "Nakagawa, Saki"

PubPharm (44)

1

Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma

enthalten in: Breast cancer research and treatment | 2024

von Nakagawa, S. | Miyashita, M. | Maeda, I. | +14

2

Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma

enthalten in: Breast cancer research and treatment | 2024

von Nakagawa, S. | Miyashita, M. | Maeda, I. | +14

3

The Fungal Metabolite (+)-Terrein Abrogates Inflammatory Bone Resorption via the Suppression of TNF-α Production in a Ligature-Induced Periodontitis Mouse Model

enthalten in: Journal of fungi (Basel, Switzerland) | 2023

von Sako, H. | Omori, K. | Nakayama, M. | +12

4

Comparative Impact of Isolated Ultrafiltration and Hemodialysis on Fluid Distribution : A Bioimpedance Study

enthalten in: Blood purification | 2022

von Akiyama, Y. | Matsuoka, R. | Masuda, T. | +14

5

The Fungal Metabolite (+)-Terrein Abrogates Ovariectomy-Induced Bone Loss and Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclastogenesis by Suppressing Protein Kinase-C α/βII Phosphorylation

enthalten in: Frontiers in pharmacology | 2021

von Sakaida, K. | Omori, K. | Nakayama, M. | +13

6

The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1

enthalten in: International immunopharmacology | 2020

von Nakagawa, S. | Omori, K. | Nakayama, M. | +13

7

The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease

enthalten in: Diabetology & metabolic syndrome | 2020

von Ohara, K. | Masuda, T. | Morinari, M. | +11

8

The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease

enthalten in: Diabetology & metabolic syndrome | 2020

von Ohara, K. | Masuda, T. | Morinari, M. | +11

9

The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease

enthalten in: Diabetology & metabolic syndrome | 2020

von Ohara, K. | Masuda, T. | Morinari, M. | +11

10

Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution : A comparison study with furosemide and tolvaptan

enthalten in: Nephrology (Carlton, Vic.) | 2019

von Ohara, K. | Masuda, T. | Murakami, T. | +14

1
2
3
4
5
Nächster »
[5]